Wedescribe a 17-year-old womanwith a family history of FMFwho suffered from recurrent fever accompanied by pains in the left chest and abdomen. During a five-year period she experienced attacks about once every six months. The metaraminol provocative test was positive. Genomic DNAextracted from peripheral blood lymphocytes from both her and her parents were analyzed by polymerase chain reaction (PCR), followed by cycle sequencing. We detected a mutation (ATG to ATA)in codon 694 in exon 10 of the FMFgene, MEFV,that resulted in a substitution of isoleucine for methionine (M694I) in both her and her father. This is the first Japanese case of FMFwith a mutation in MEFVidentified in the family history. (Internal Medicine 42: 761-764, 2003) 
Primers are the same as described in the International FMFConsortium (4). FMF(10), was performed and registered positive. Nineteen hours after metaraminol injection (10 mg), the patient experienced left shoulder pain, followed by left chest pain 43 hours later. The pain was mild and similar to her spontaneous attacks. A clinical diagnosis of FMFwas madefor this patient on the basis of satisfying one of the minor criteria (1 1), incomplete abdominal and chest pain, and 5 supportive criteria including a family history, onset less than 20 years, spontaneous remission, a transient inflammatory response and symptom-free periods between attacks. With informed consent from the patient and her parents, DNAwas extracted from peripheral blood lymphocytes by standard techniques. Wealso extracted DNAfrom Japanese humanplacenta as normal control after obtaining informed consent from the donor. Sections of exons 1 to 10 of MEFV were analyzed by PCR, followed by cycle sequencing using Big Dye Sequencing Chemistry (Applied Biosystems, Foster City, CA) with an ABI PRISM 310 genetic analyzer (Applied Biosystems). The primers are listed in Table 2 . A mutation in MEFVwas identified in both the patient and her father (Fig. 1) . The mutation (ATG to ATA) at codon 694 resulted in a substitution of isoleucine for methionine (M694I).
In addition, four single base substitutions were identified in the patient. These substitutions corresponded to the polymorphisms previously described (3). Her father had an additional four polymorphisms, of which three substitutions were also identified in her mother (Table 3) all subjects and human placenta even with newly designed primers for the exon. Colchicine 1-2 mg per day successfully reduced the frequency and severity of the attacks and provided symptomatic relief of the chest and abdominal pains.
Discussion
In the absence of specific laboratory tests, the diagnosis of FMFis primarily based on a combination of clinical manifestations, family history and ethnicity. Prominent symptoms include fever, abdominal pain, chest pain, arthralgia and erysipelas-like erythema. A typical acute attack with concurrent fever and serositis lasts from 1 to 4 days and most patients remain free of symptoms between episodes. The frequency of the attacks varies from once a week to once every [3] [4] months. In the present case, the family history raised the suspicion of a diagnosis of FMF. The diagnosis was confirmed after satisfying one of the minor criteria and 5 of the supportive criteria that were proposed by Livneh et al (ll). Onadmission to hospital, the patient was free of symptoms. The metaraminol provocative test was performed to further confirm the clinical diagnosis. This test is based on the theory that FMF is caused by impairment of catecholamine metabolism. As metaraminol acts as a sympathomimetic agent that stimulates endogenous catecholamine release, one expects that venous injection of metaraminol into a patient with FMF will induce FMF-like symptoms. Some cardiac side effects have been reported with metaraminol challenge for patients without a history of cardiac disease (12) , namely bigeminy and angina pectoris. In the present case, no arrhythmia wasobserved. Webelieve that the metaraminol provocative test is useful in diagnosing FMFand should be performed with close monitoring for potential cardiac side effects.
The gene responsible for FMF, MEFV,has been mapped to chromosome 16pl3.3 (13) . The protein encoded by MEFV, named pyrin (3) or marenostrin (4), is exclusively expressed in granulocytes. Pyrin /marenostrin is likely to be a negative regulator of granulocyte-mediated inflammation, however, the molecular mechanisms are not understood. Several MEFV mutations, M694V, M694I, M680I and V726A (3, 4), were initially identified in exon 10. Subsequently, additional mutations, most of which are less common, have been found inexons 10, 3, 2 and5. In this report we sequenced regions containing all known mutations. Previously designed primers (14) successfully amplified exons 1 and 3 to 10, while we failed to amplify exon 2 even with our own newly designed primers. The mutation analysis revealed only the M694Imutation in exon 10 of both the patient and her father, but no mutations were found in her mother. In general, most FMFis known to be inherited autosomal recessively (1), which is inconsistent with the present that would be inherited autosomal dominantly. Yuval et al reported that autosomal dominant inheritance was found in 2 of 77 families with FMF, although there was no survey on the gene mutations (15) . There has been increasing numbers of FMFpatients with only one mutation (15, 16) . Booth et al (17) , who reported 3 of 5 families with simple heterozygosity for pyrin M694 delletion or with a M694I-E148Qcomplex allele. Cazeneuve et al reported that only one FMFallele mutation was identified in 6 patients of sporadic 90 Armenian FMF, namely M694V/ unidentified allele in two patients, M680I/unidentified allele in two patients, V726A/unidentified allele in one patient, and complex allele with E148Q, P369S and R408Q/unidentified allele in one patient (16) . Further there were no mutations in two FMFalleles in three of their patients (16) . With regard to M694I mutation, a FMFpatient with the single mutation in a single allele has never been demonstrated to date. It is possible, therefore, that the mutation(s) in the present case may exist in only M694and/or in another site not identified to date, especially in exon 2 because of the amplification failure in the present study. In summary, we have described a Japanese patient with FMF, whose diagnosis was confirmed by the identification of the MEFVmutation, M694I, a mutation previously demonstrated in Mediterranean ethnic groups. physician unfamiliar with this disease, who has difficulty establishing a diagnosis of FMF, genetic analysis would be a convenient and convincing methodof confirming the correct diagnosis.
